Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 105

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 105
---
 is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the
Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue
as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

At-The-Market Facility

On August 31, 2022, the Company entered into a
Sales Agreement with Cantor, pursuant to which the Company may issue and sell from time-to-time shares of the Company’s Common Stock
through Cantor, subject to the terms and conditions of the Sales Agreement. During the year ended June 30, 2024, the Company sold 333,749
shares of its Common Stock under the Sales Agreement with Cantor for total net proceeds of approximately $9.3 million after 3% commissions
and cost totaling approximately $377,000. During the three months ended September 30, 2024, the Company sold approximately 2,143 shares
of its Common Stock under the Sales Agreement for total net proceeds of approximately $6,400 after 3% commissions and offering costs totaling
approximately $200. On September 25, 2024, the Company filed a prospectus supplement to suspend sales under the Controlled Equity Offering
Sales Agreement.

Offerings

On March 6, 2024, the Company closed the best
efforts public offering (the “March 2024 Offering”) of 1,500,000 shares (the “Shares”) of Common Stock, pre-funded
warrants (the “Pre-funded Warrants”) to purchase 600,000 shares of Common Stock, and warrants to purchase up to 1,050,000
shares of Common Stock (the “Common Warrants”) (CUSIP 09074F132) at a combined public offering price of $10.00 per Share,
or Pre-funded Warrant, and the associated Common Warrant. The gross proceeds to the Company from the March 2024 Offering were approximately
$21 million, before deducting placement agent fees and offering expenses of approximately $2.5 million. Upon closing of the March 2024
Offering, the Company issued the placement agent a warrant (“Placement Agent’s Warrant”) to purchase 105,000 shares
of Common Stock exercisable at a per share price of $12.50, which was equal to 125% of the public offering price per Share. The Placement
Agent’s Warrant